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ABSTRACT  
Background: High-sensitivity cardiac troponin (hs-cTn) may allow an earlier diagnosis of 
acute myocardial infarction (AMI).  
Methods: We prospectively enrolled 1148 (derivation cohort) and 517 (external validation 
cohort) unselected patients presenting with suspected AMI to the emergency department. 
Final diagnosis was adjudicated by two independent cardiologists. Hs-cTnT was 
measured at presentation and after two hours. A diagnostic algorithm incorporating hs-
cTnT values at presentation and absolute changes within the first two hours was derived.  
Results: AMI was the final diagnosis in 16% of patients in the derivation and 9.1% in the 
validation cohort. The 2h algorithm developed in the derivation cohort classified 60% of 
patients as “rule-out”, 16% as “rule-in” and 24% in the “observational- zone”. Resulting 
sensitivity and negative predictive value (NPV) were 99.5% and 99.9% for rule-out, and 
specificity and positive predictive value (PPV) 96% and 78% for rule-in. Applying the 2h 
triage algorithm in the external validation cohort, 78% of patients could be classified as 
“rule-out”, 8% as “rule-in” and 14% in the “observational-zone”. Resulting sensitivity and 
NPV were 96% and 99.5% for rule-out and specificity and PPV 99% and 85% for rule-in. 
Cumulative 30-day survival rates were 100%, 98.9% and 95.2% (p<0.001) and 
100%,100% and 95% (p<0.001) in patients classified as “rule-out”, “observational-zone” 
and “rule-in” in the two cohorts respectively.  
Conclusions:   A simple algorithm incorporating hs-cTnT baseline values and absolute 
changes over two hours allowed a triage towards safe rule-out, or accurate rule-in, of AMI 
in the vast majority of patients with only 20% requiring more prolonged monitoring and 
serial blood sampling. 
Key Words: Acute myocardial infarction – high-sensitive Troponin – Diagnostic algorithm 
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Introduction 
Patients with symptoms suggestive of acute myocardial infarction account for about 10% 
of all emergency department consultations.1 Electrocardiography (ECG) and cardiac 
troponin (cTn) form the diagnostic cornerstones and complement clinical assessment.2-5 
The major limitation of former generation cTn assays is a delayed increase of circulating 
levels mandating serial sampling for 6-12 hours, which can result in both delayed 
diagnosis of acute myocardial infarction (“rule-in”) as well as delayed exclusion of acute 
myocardial infarction  (“rule-out”).2, 4-7  
Sensitive and high-sensitivity cardiac troponin (hs-cTn) assays have enabled 
measurement of lower cTn concentrations.8 These assays have been shown to improve 
the diagnostic accuracy for acute myocardial infarction at presentation, and it has been 
suggested that more rapid rule-in and rule-out of acute myocardial infarction might be 
feasible with those tests.9-11 On the other hand, improvement in assay sensitivity 
significantly increases the proportion of positive hs-cTn tests due to various acute and 
chronic conditions with cardiac involvement other than acute myocardial infarction.12-15 As 
a consequence, the positive predictive value (PPV) of an elevated hs-cTn level for acute 
myocardial infarction has decreased,9, 10, 16, 17 causing confusion amongst physicians 
treating patients with possible acute myocardial infarction.18  
We recently developed a simple algorithm using hs-cTnT levels that allowed a 
triage towards a safe rule-out as well as an accurate rule-in of acute myocardial infarction 
within one hour in 77% of unselected acute chest pain patients.19 Some experts however 
were concerned that the one-hour approach may not be safe when used in different ED 
populations and others have questioned the practicability of a 1-hour algorithm. 
Furthermore, external validation of the algorithm is pending.20  
The aim of this study therefore was to develop an algorithm for rapid rule-in and 
rule-out of acute myocardial infarction from a European multicentre cohort using hs-cTnT 
levels and absolute changes within the first two hours, and to externally validate the 
derived algorithm in a non-European cohort.  
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Methods 
Study design and population derivation cohort 
Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) is an ongoing 
prospective international multicenter study designed and coordinated by the University 
Hospital Basel (ClinicalTrials.gov registry, number NCT00470587).9, 21 From April 2006 to 
August 2011, a total of 2195 unselected patients presenting to the emergency department 
with symptoms suggestive of acute myocardial infarction such as acute chest pain and 
angina pectoris with an onset or peak within the last 12 hours were recruited. Patients with 
terminal kidney failure requiring dialysis were excluded. The study was carried out 
according to the principles of the Declaration of Helsinki and approved by the local ethics 
committees. Written informed consent was obtained from all patients.  
Patients with ST-segment elevation myocardial infarction (n=83) and missing 
samples (n=964) were excluded from this analysis, which left 1148 patients available. 
Baseline characteristics of patients with missing samples are shown in supplemental 
Table 1. These patients did not differ significantly from the study population with the 
exception of a slightly higher rate of acute myocardial infarction (20% vs. 16%, p=0.03). 
The most common reasons for missing samples after 2 hours were early transfer to the 
cath lab or CCU and diagnostic procedures around the 2h window that precluded blood 
draw at 2h, but not the draw of earlier or future follow-up samples.  
 
Study design and population validation cohort 
From November 2008 to February 2011, a total of 978 unselected patients presenting to 
the emergency department of the Royal Brisbane and Women’s Hospital with symptoms 
of possible acute myocardial infarction were recruited. Criteria for enrollment included age 
≥18 years of age, with at least 5 min of symptoms where the attending physician planned 
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to perform serial cTn tests. The American Heart Association case definitions for possible 
cardiac symptoms were used (i.e., acute chest, epigastric, neck, jaw, or arm pain; or 
discomfort or pressure without an apparent noncardiac source).22 Patients were excluded 
for any of the following: a clear cause other than acute coronary syndrome for the 
symptoms (e.g., examination findings of pneumonia), inability to provide informed consent, 
staff considered recruitment to be inappropriate (e.g., receiving palliative treatment), 
transfer from another hospital, pregnancy, previous enrollment, or inability to be contacted 
after discharge. Perceived high risk was not used as an exclusion criterion. The study was 
carried out according to the principles of the Declaration of Helsinki and approved by the 
local ethics committees. Written informed consent was obtained from all patients. Patients 
with ST-segment elevation myocardial infarction (n=23), patients who stated that their first 
episode of pain commenced >12 hours before presentation (n=279) and patients with 
missing samples (n=159) were excluded from this analysis, which left 517 patients 
available. Baseline characteristics of patients with onset of symptoms >12 hours and 
missing samples are shown in supplemental Table 2. Those patients did not differ 
significantly from the study population (all p-values >0.05). 
 
Routine clinical assessment 
Patients were managed according to local hospital protocols, including clinical history, 
physical examination, 12-lead ECG, continuous ECG-monitoring, pulse oximetry, standard 
blood tests and chest radiography. Clinical blood draws for local cTn measurement were 
performed at presentation, and then 6-12 h afterwards. Management of patients was at 
the discretion of the attending physician.  
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Investigational hs-cTnT analysis 
Blood samples for determination of hs-cTnT (Roche Diagnostics) were collected in serum 
tubes at presentation to the emergency department and after 2 hours. Serial sampling was 
discontinued when the diagnosis of acute myocardial infarction was certain and treatment 
required transferring the patient to the catheter laboratory or coronary care unit. After 
centrifugation, samples were frozen at -80°C until assayed in a blinded fashion using the 
Elecsys 2010 (Roche Diagnostics) in a dedicated core laboratory. For hs–cTnT, limit of 
blank (LoB) and limit of detection (LoD) have been determined to be 3 ng/l and 5 ng/l, an 
imprecision corresponding to 10% coefficient of variation (CV) was reported at 13 ng/L 
and the 99th-percentile of a healthy reference population at 14 ng/L.8 In 876 recruited 
patients (Patient 1196-2072) in the APACE cohort and in all 517 patients of the Brisbane 
cohort, hs-cTnT measurements were performed with hs-cTnT assay lots that required 
revision of the calibration curve. After consultation with the manufacturer (Roche 
Diagnostics), these affected hs-cTnT values were re-calculated using the most appropriate 
methods for both settings (non-linear regression in APACE and recalibration of the 
measurement platform in Brisbane).23  Glomerular filtration rate was calculated using the 
abbreviated Modification of Diet in Renal Disease formula.24 
 
Adjudication of final diagnosis  
Final diagnoses were adjudicated by independent cardiologists not directly involved in 
patient care. Adjudication was based on all available medical records (including patient 
history, physical examination, all laboratory testing including cTn levels, radiologic testing, 
ECG, echocardiography, cardiac exercise test, lesion severity and morphology in coronary 
angiography, discharge summary) pertaining to the patient from the time of emergency 
department presentation to 60-day follow-up. While discharge diagnoses often were 
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correct and in agreement with the final adjudicated diagnosis, there were also cases 
where those diagnoses needed to be revised, most often because more information 
became available from medical testing during early follow-up, and more rarely, because 
the discharge diagnosis was not in agreement with the Universal Definition of acute 
myocardial infarction.  
Acute myocardial infarction was defined and cTn levels interpreted as recommended in 
current guidelines.2, 3, 5, 25 In brief, acute myocardial infarction was diagnosed when there 
was evidence of myocardial necrosis with a significant rise and/or fall in a clinical setting 
consistent with myocardial ischemia. Patients with acute myocardial infarction were further 
subdivided into acute myocardial infarction type 1 (primary coronary events) and acute 
myocardial infarction type 2 (ischemia due to increased demand or decreased supply, for 
example tachyarrhythmias or hypertensive crisis).2, 3 Details on the adjudication in the 
derivation and validation cohort are given in the online supplemental appendix.  
 
Follow-up and clinical endpoints 
After hospital discharge, patients were contacted after 3 and 12 months (APACE) and at 6 
weeks and 12 months (Brisbane) by telephone calls or in written form. Information 
regarding death was furthermore obtained from the patients’ hospital notes, the family 
physician’s records and the national registry on mortality. The primary prognostic endpoint 
was 30 days all-cause mortality.  
 
Algorithm development and validation 
The algorithm for use of hs-cTnT was developed in the derivation cohort (APACE). The 
algorithm incorporates both hs-cTnT levels and absolute hs-cTnT changes within the first 
two hours. Selection of these two parameters was based on the previously published very 
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high diagnostic accuracy of the combination of absolute levels and absolute changes.21, 26 
Optimal thresholds for rule-out were selected to allow for the highest sensitivity and 
negative predictive value (NPV) possible. Optimal thresholds for rule-in were obtained 
based on a classification and regression tree (CART) analysis.27, 28 The CART algorithm 
provides a sequence of partitions of a given data set aimed at optimizing the prediction of 
a binary outcome variable. Each subsequent partition is obtained by splitting one of the 
preceding partition sets (nodes) into two parts. If quantitative predictor variables are used, 
a pair of new nodes is obtained by splitting an existing node at a given threshold value of 
one of these variables. The algorithm stops if no further improvement is possible or if any 
further split would violate a predefined criterion (e.g., on the minimal node size).27, 28 
Nodes in the CART tree were constrained to have a minimal number of cases of 20 in 
parent and child nodes. In addition to baseline hs-cTnT levels and absolute hs-cTnT 
changes within the first hour, age (as a continuous variable), gender, ECG features (signs 
of ischemia or not) and time since onset of symptoms (as a continuous variable) were 
included in the CART model as well.  
The algorithm developed in the derivation cohort was then tested for diagnostic 
accuracy in the validation cohort (Brisbane). Subgroup analyses focused on the 
performance of the algorithm in patients presenting early (<6h) after the onset of 
symptoms, on patients with troponin levels below the 99th percentile and on patients with a 
TIMI risk score ≤ 1 versus and those with a TIMI risk >1.29 
 
Statistical analysis 
Continuous variables are described as mean ± SD or median with interquartile range 
(IQR), categorical variables by numbers and percentages. Differences in baseline 
characteristics between patients with and without acute myocardial infarction and between 
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patients in the derivation and validation cohort were assessed using the Mann-Whitney U 
test for continuous variables and the Pearson Chi-square test for categorical variables.  
Survival during 30-days of follow up according to the classification provided by the 
hs-cTnT algorithm was plotted in Kaplan-Meier curves and the log-rank test was used to 
assess differences in survival between groups. Hazard ratios (HR) and 95% confidence 
intervals (CI) were obtained from Cox proportional hazard models to quantify the 
magnitudes of group differences.  
All hypothesis testing was two-tailed and p-values < 0.05 were considered 
statistically significant. All statistical analyses were performed using SPSS for Windows 
19.0 (SPSS Inc, Chicago, IL).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Results 
Characteristics of patients 
Baseline characteristics of the patients in the derivation cohort (n=1148) and the validation 
cohort (n=517) are shown in Tables 1 and 2. Acute myocardial infarction was the final 
diagnosis in 16.3% of patients in the derivation cohort (13.7% type 1 acute myocardial 
infarction, 2.6% type 2 acute myocardial infarction) and 9.1% in the validation cohort 
(5.6% type 1 acute myocardial infarction, 3.5% type 2 acute myocardial infarction). Of all 
patients, discharge within less than 24h occurred in 46% of patients in the derivation and 
40% of the validation cohort. Time from onset of symptoms to first study blood draw was 
3h (IQR 2-7) in the derivation cohort and 2h (IQR 1-5) in the validation cohort. 
 
Hs-cTnT levels at presentation and after 2 hours 
Levels of hs-cTnT at presentation and after 2 hours were significantly higher in patients 
with acute myocardial infarction compared to those without (Figure 1). Levels at 
presentation in men and women were similar in the overall cohorts and in the subset of 
patients with acute myocardial infarction (data not shown).  
Of all patients, 36% (derivation cohort) and 22% (validation cohort) had hs-cTnT 
levels above the 99th percentile of healthy individuals at baseline or after 2 hours. Using 
this value as a qualitative cut-off level to diagnose acute myocardial infarction resulted in a 
sensitivity of 98%, a NPV of 99.6%, a specificity of 73% and a PPV of 42% in the 
derivation cohort and of 96%, 99.5%, 86% and 40% in the validation cohort. 
 
Derivation of the hs-cTnT algorithm for the diagnosis of acute myocardial infarction  
An algorithm incorporating hs-cTnT baseline values and absolute hs-cTnT changes 
within the first two hours was developed in the derivation cohort. For “rule-out” of acute 
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myocardial infarction, the optimal thresholds were selected to allow for the highest 
sensitivity and NPV possible. The rule-out criteria were defined as a maximal hs-cTnT 
level within the first 2 hours of <14 ng/l and an absolute change within the first two hours 
of <4 ng/l. For “rule-in” of acute myocardial infarction, the optimal thresholds as obtained 
by CART analysis were either a maximal hs-cTnT value within the first 2 hours of ≥53 ng/l 
or an absolute change in hs-cTnT within the first 2 hours of ≥10 ng/l. The additional 
variables in the CART analysis (age, gender, ischemic ECG changes and time since onset 
of symptoms) did not improve the accuracy and did not emerge as contributors to the final 
decision tree. Patients fulfilling neither of the above criteria for rule-in or for rule-out were 
classified in a third group called “observational zone”. The diagnostic performance of the 
algorithm in the derivation cohort is shown in Figure 2 A. It classified 683 (60%) patients 
as “rule-out”, 187 (16%) as “rule-in” and 278 (24%) patients in the “observational zone”. 
Further details on the patients classified in the observational zone are given in the 
supplementary appendix. One patient with acute myocardial infarction was missed by the 
algorithm (see supplemental Table 3 for detailed patient characteristics), which resulted in 
a sensitivity and NPV of 99.5% and 99.9% for rule-out. Specificity and PPV for rule-in 
were 96% and 78%. The accuracy of the algorithm was very similar for men and women 
(Sensitivity/ NPV/ Specificity/ PPV 99.3 vs. 100%, 99.8 vs. 100%, 97 vs. 94% and 82 vs. 
70% for male vs. female).  
 
Validation of the hs-cTnT algorithm for the diagnosis of acute myocardial infarction  
The algorithm was tested in the validation cohort. The performance in the validation cohort 
is depicted in Figure 2 B.  
Applying the hs-cTnT algorithm to the validation cohort, 402 (78%) patients could be 
classified as “rule-out”. Two patients with acute myocardial infarction were missed (see 
supplemental Table 3 for detailed patient characteristics), resulting in a sensitivity and 
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NPV of 96% and 99.5%, respectively. Additionally, 40 (8%) patients were classified as 
“rule-in”, which resulted in a specificity and PPV of 99% and 85%.  Taken together, the 
algorithm allowed a definite diagnosis after 2h in 86% of patients (either “rule-in” or “rule 
out”). The remaining 75 (14%) patients were classified in the “observational zone”. Further 
details on the patients classified in the observational zone are given in the supplementary 
appendix. The final adjudicated diagnoses in patients falsely ruled-in for acute myocardial 
infarction (n=6) based on the algorithm were, acute heart failure (n=3), stable coronary 
artery disease (n=1) and pericarditis (n=2). The accuracy of the algorithm was similar for 
men and women. Sensitivity and NPV for rule out were 96% and 99.6% for male versus 
96% and 99.4% for female; and specificity and PPV for rule in were 98% and 76% for 
male versus 100% and 100% for female. The algorithm performed equally well in patients 
presenting ≤ 6 hours or > 6 hours after the onset of symptoms, in those with a hs-cTnT 
level below the 99th percentile and in patients with a TIMI risk score ≤ 1 as well as those 
with a TIMI risk score >1 (see supplemental appendix for detailed results).  
 
Prognostic performance of the hs-cTnT algorithm to predict death during follow-up 
In the derivation cohort, there were twelve deaths within 30 days and forty-seven within 1 
year. Survival up to 30 days of follow-up was significantly associated with the categories 
“rule-out”, “observational zone” and “rule-in” as classified by the hs-cTnT algorithm. 
Cumulative 30-days survival rates in Kaplan Meier curves were 100%, 98.9% and 95.2% 
(p<0.001 by log rank test) in the respective categories (Figure 3 A). This pattern continued 
up to a follow-up of 1 year with cumulative survival rates of 98.8%, 93.4% and 87.3% 
(p<0.001 by log rank test).  
In the validation cohort, there were two deaths within 30 days and eight within 1 
year. Survival up to 30 days of follow-up was significantly associated with the categories 
“rule-out”, “observational zone” and “rule-in” as classified by the hs-cTnT algorithm. 
Cumulative 30-days survival rates in Kaplan Meier curves were 100%, 100% and 95% 
(p<0.001 by log rank test, Figure 3 B). Similarly, this pattern continued up to a follow-up of 
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1 year with cumulative survival rates of 100%, 96% and 87.5% (p=<0.001 by log rank 
test).  
The combined endpoint of myocardial infarction and cardiac death within 30 days 
was also analyzed, which occurred in 191 patients in the derivation cohort and in 48 
patients in the validation cohort. This endpoint was also significantly associated with the 
categories “rule-out”, “observational zone” and “rule-in” as classified by the algorithm and 
occurred in 0.4%, 15.5% and 77.5% of patients in the respective categories of the 
derivation cohort (p<0.001 by log rank test) and in 0.7%, 14.7% and 85.0% of patients the 
validation cohort (p<0.01 by log rank test).  
 
Impact of Type 1 vs. Type 2 Acute Myocardial Infarction 
There was a trend towards higher cardiac troponin levels at presentation in patients with 
acute myocardial infarction type 1 compared to acute myocardial infarction type 2 (63 ng/l 
(IQR 20-139) vs. 40 ng/l (IQR 19-88), p=0.17 in the derivation cohort; and 65 ng/l (IQR 36-
107) vs. 27 ng/l (IQR 16-103), p=0.06 in the validation cohort). Absolute changes within 
the first 2 hours were significantly higher in acute myocardial infarction type 1 compared to 
type 2 patients in the derivation cohort (19 ng/l (IQR 8-62) vs. 11 ng/l (IQR 4-25), p=0.03), 
but not in the validation cohort (23 ng/l (IQR 7-96) vs. 20 ng/l (IQR 1-37), p=0.15). One 
year cumulative survival was comparable for patients with type 1 and type 2 acute 
myocardial infarction (89.4% vs. 86.1%, p=0.25 in the derivation cohort; and 86.2% vs. 
88.9%, p=0.82 in the validation cohort).  
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Discussion 
Using two large, independent and well-characterized prospective cohorts of 
unselected patients presenting with symptoms suggestive of acute myocardial infarction, 
this study aimed to develop an algorithm for rapid rule-in and rule-out of acute myocardial 
infarction from a European cohort using hs-cTnT baseline levels and absolute changes 
within the first two hours and to externally validate the derived algorithm in a non-
European cohort. We report three major novel findings:  
First, we developed and validated a simple algorithm incorporating hs-cTnT values 
at baseline and after two hours as well as the absolute changes over two hours.  
 Using this algorithm in the validation cohort, a safe rule-out and accurate rule-in of 
acute myocardial infarction could be performed within 2 hours with a sensitivity and NPV 
of 96% and 99.5%, and a specificity of 99% and a PPV of 85%. Second, the use of this 
algorithm significantly shortens the time needed for rule-out and rule-in of acute 
myocardial infarction and may obviate the need for prolonged monitoring and serial blood 
sampling in 8 out of 10 unselected patients presenting with acute chest pain. Third, 30-
days survival was 100% in patients ruled-out for acute myocardial infarction, which 
underscores the safety of early discharge for these patients with further out-patient 
management as deemed clinically appropriate.  
Although the hs-cTn assays have been shown to increase the diagnostic accuracy 
at presentation,9, 10 simple “how to use” instructions for clinical decision making are still 
lacking, but critically needed to take advantage of the high-sensitive assays and to shorten 
the time to rule-in and rule-out acute myocardial infarction.2-5, 18  The current analyses 
corroborate and extend recent observations that a simple algorithm using hs-cTnT levels 
seems to allowed a safe rule-out as well as an accurate rule-in of acute myocardial 
infarction within one hour in many patients.19 The external validation in a non-European 
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cohort resulting in similar accuracy and safety is reassuring and another important step 
towards a more widespread use in the emergency department.  
 With older cTn assays, the terms “troponin positive” and “troponin negative” were 
often used, and resulted in a high PPV and specificity, but low sensitivity. The hs-cTn 
assays are more sensitive and detect smaller amounts of cardiomyocyte damage more 
rapidly.8 A “one size fits all” single cut-off criterion for simultaneous rule-in and rule-out 
would however result in either too many false positive results for patients with various 
acute and chronic conditions with cardiac involvement other than acute myocardial 
infarction, 12-15 or would not take advantage of the sensitivity of the hs-cTn assays and 
continue to miss small acute myocardial infarctions. Our study rather proposes the use of 
2 different criteria for rule-in and rule-out resulting in 3 diagnostic groups, with only roughly 
20% of the patients being classified in an “observational zone” requiring prolonged 
monitoring and serial blood sampling. This concept of a grey zone is well known from 
other fields of acute cardiac care such as the use of natriuretic peptides for the diagnosis 
of acute heart failure.30  
The proportion of chest pain patients in an emergency department indeed suffering 
from acute myocardial infarction can vary remarkably according to the organization of the 
emergency medical services. Accordingly, acute myocardial infarction proportions 
reported from recent large chest pain cohort studies have ranged from 3% to 23%.10, 31-35 
It’s important for the generalizability of the algorithm that its performance was equally well 
in a higher risk cohort (derivation cohort, acute myocardial infarction rate 16%) and a 
lower risk cohort (validation cohort, acute myocardial infarction rate 9%).  
For some but not all of the hs-cTn assays differences in the 99th percentile between 
women and men have been reported,36, 37 which has recently brought up the option of 
possibly using a gender-specific 99th percentile. In our study, levels of hs-cTnT in patients 
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with symptoms suggestive of acute myocardial infarction were similar in men and women, 
and the accuracy of the algorithm was very similar for men and women. Furthermore, 
introduction of gender in CART analysis did not improve accuracy. Given that the current 
standard of care worldwide in the diagnosis of acute myocardial infarction is the use of 
uniform cut-off levels for hs-cTnT and that clinical applicability of the algorithm would be 
significantly lower if complexity was increased by introducing gender specific values, we 
elected to not use gender specific cut-off values for our algorithm.   
 This study complements prior work on a 2h algorithm that had used different 
diagnostic tests.32,38 First, combining the TIMI scores and a point-of-care biomarker panel 
including standard cTn, creatine kinase MB, and myoglobin  classified 10% of patients 
with chest pain as low-risk and suitable for early discharge.32 Second, a combination of 
the TIMI score with sensitive cTn assays allowed 20% of chest pain patients to be 
identified as low risk.38 The algorithm derived and externally validated in the present study 
clearly outperformed those previous algorithms: Rule-out of acute myocardial infarction 
was possible in 60% respectively 78% and rule-in of acute myocardial infarction in 16% 
respectively 8% of all chest pain patients within 2h in the two cohorts with very high 
diagnostic accuracy. Roughly 20% of the patients fulfilled neither criterion, were classified 
“observational zone” and would require more than 2h for assessment, and many of them 
probably will need additional diagnostic testing such as coronary angiography, exercise 
stress test or echocardiography. Compared to the 3-6h interval for a cTn follow-up sample 
recommended in current guidelines,2-4 the shortening to a 2h follow-up period in the vast 
majority of patients represent a major advance in clinical care. It also complements our 
previously published 1h algorithm19 as well as the recently presented but not yet published 
TRAPID-AMI study, both of which used a rapid triage algorithm concept similar to the one 
presented here. This study and the two other 1h-algorithm studies provide data driven 
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results from real–world patients that to some extent may contradict theoretical 
considerations regarding the precision of the hs-cTnT assay and suggest that it allows the 
reliable detection of even small absolute changes.5,26  
For the derivation cohort, specificity and positive predictive value were improved 
from 73% and 42% when only using absolute hs-cTnT levels to 96% and 78% respectively 
using the 2h hs-cTnT algorithm. Similarly, in the validation cohort, specificity and positive 
predictive value improved from 86% and 40% with absolute hs-cTnT levels to 99% and 
85% respectively when using the 2h hs-cTnT algorithm. It is important to highlight that 
acute myocardial infarction remains a clinical diagnosis and that in clinical practice hs-
cTnT levels are interpreted in conjunction with all other available information including 12-
lead ECG, patient history and examination, and other diagnostic investigations. When felt 
appropriate, those parameters should over-rule the recommendation given by the 
algorithm. The accuracy of the algorithm in clinical practice, when used in conjunction with 
the above information and supported ideally by an automated electronic laboratory 
reporting system, will likely be even higher than reported in this hs-cTnT only analysis and 
will in especial further increase the PPV.  
Potential limitations of the current study merit consideration. First, our study was 
conducted in emergency department patients with symptoms suggestive of acute 
myocardial infarction and the diagnostic accuracy of the algorithm will only be upheld in 
cohorts with a similar pretest probability. Second, the data presented was obtained from 
prospective observational studies. Studies applying the diagnostic algorithm prospectively 
for clinical decision-making are warranted. Third, different troponin assays were used 
clinically in the participating centres and might have influenced the clinical management of 
the patients. Fourth, we used one specific hs-cTn assay for derivation and validation of the 
algorithm (hs-cTnT). Different sensitive and high sensitive assays vary considerably with 
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regards to the amount of patients detected with elevated troponin levels. We hypothesize 
that similar algorithms can be developed for other hs-cTn assays,39 but this requires 
similar derivation and validation in chest pain patient cohorts first.  
 In conclusion, using a simple algorithm incorporating hs-cTnT values at 
presentation and after two hours as well as absolute changes within the first two hours, a 
safe rule-out or accurate rule-in of acute myocardial infarction could be performed within 
two hours in the vast majority of patients presenting with chest pain. The use of this 
algorithm seems to be safe, significantly shortens the time needed for rule-out and rule-in 
of acute myocardial infarction and leaves only 20% of chest pain patients that require 
more prolonged monitoring and serial blood sampling.  
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Figure Legends 
Figure 1    Levels of hs-cTnT absolute changes within the first 2 hours 
 
Hs-cTnT levels at presentation to the emergency department and after 2 hours and 
absolute changes in patients with and without acute myocardial infarction (AMI) in the 
derivation (A) and validation cohort (B). Boxes represent IQR’s, while whiskers display 
ranges (without outliers further than 1.5 IQR’s from the respective end of the box).  
 
 
 
 
Performance of the algorithm classifying patients into “rule-out”, “observational zone” and 
“rule-in”. Results are displayed for the derivation cohort (Panel A) and for the validation 
cohort (Panel B). hs-cTnT values are presented in ng/l. 0h/2h = hs-cTnT at presentation 
and after 2 hours. Delta 2h = absolute change of hs-cTnT within the first two hours; NPV = 
negative predictive value; PPV = positive predictive value.  
 
 
 
Kaplan Meier curves displaying survival during 30-days of follow-up in the derivation 
(Panel A) and validation (Panel B) cohort according to the classification into “rule-out”, 
“observational zone” and “rule-in” provided by the hs-cTnT one hour algorithm. Differences 
in survival were assessed using the log-rank test. 
Figure 2 Performance of the hs-cTnT algorithm for diagnosis of acute myocardial infarction in the derivation and validation cohort  
Figure 3 Kaplan Meier curves for the cumulative survival according to 
classification provided by the hs-cTnT algorithm 
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Table 1  Baseline Characteristics of the Patients in the Derivation Cohort 
 All patients Acute MI Others P Value 
 (n=1148) (n=187) (n=961)  
Age – yr  62 (51 – 74) 71 (59 – 79) 61 (50 – 73) < 0.001 
Male gender – no. (%) 795 (69) 139 (74) 656 (68) 0.58 
Risk factors – no. (%)     
Hypertension 741 (65) 143 (77) 598 (62) <0.001 
Hypercholesterolemia 538(47) 109 (58) 429 (45) 0.001 
Diabetes 215 (19) 48 (26) 167 (17) 0.008 
Current smoking 292 (25) 46 (25) 246 (26) 0.80 
History of smoking 427 (37) 79 (42) 348 (36) 0.11 
History – no. (%)     
Coronary artery disease 412 (36) 91 (49) 321 (33) <0.001 
Previous myocardial infarction 280 (24) 60 (32) 220 (23) 0.007 
Previous revascularization 325 (28) 61 (33) 264 (28) 0.15 
Peripheral artery disease 78 (7) 23 (12) 55 (6) 0.001 
Previous stroke 57 (5) 18 (10) 39 (4) 0.001 
Creatinine clearance - (ml/min/m2) 91 (73 – 108) 83 (62 – 104) 92 (75 – 109) < 0.001 
ECG findings – no. (%)†     
Left bundle branch block 38 (2) 16 (9) 22 (2) <0.001 
ST-segment elevation 20 (2) 1 (1) 19 (2) 0.17 
ST-segment depression 99 (9) 46 (25) 53 (6) < 0.001 
T-wave inversion 88 (8) 19 (10) 69 (7) 0.16 
No significant ECG abnormalities 903 (79) 105 (56) 798 (83) < 0.001 
† ECG denotes electrocardiogram; numbers are presented as median (IQR) or numbers (%) 
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Table 2  Baseline Characteristics of Patients in the Validation Cohort 
 All patients Acute MI Others P Value 
 (n=517) (n=47) (n=470)  
Age – yr  54 (45 – 65) 69 (59-82) 53 (44 – 64) < 0.001 
Male gender – no. (%) 316 (61) 25 (53) 291 (62) 0.24 
Risk factors – no. (%)     
Hypertension 268 (52) 32 (68) 236 (50) 0.02 
Hypercholesterolemia 269 (52) 32 (68) 237 (50) 0.02 
Diabetes 75 (15) 10 (21) 65 (14) 0.17 
Current smoking 127 (25) 9 (19) 118 (25) 0.37 
History of smoking 196 (38) 20 (43) 176 (37) 0.49 
History – no. (%)     
Coronary artery disease 135 (26) 25 (53) 110 (23) <0.001 
Previous myocardial infarction 103 (20) 18 (38) 85 (18) 0.001 
Previous revascularization 83 (16) 12 (26) 71 (15) 0.06 
Peripheral artery disease 11 (2) 5 (11) 6 (1) <0.001 
Previous stroke 59 (11) 6 (13) 53 (11) 0.76 
Creatinine clearance - (ml/min/m2) 77 (64-90) 83 (73-130) 76 (64-88) 0.002 
ECG findings – no. (%)†     
ECG indicative of AMI 5 (1) 2 (4) 3 (1) 0.02 
ECG indicative of ischemia not 
known to be old 20 (4) 10 (21) 10 (2) <0.001 
ECG indicative of ischemia known 
to be old 27 (5) 5 (11) 22 (5) 0.08 
No significant ECG abnormalities 465 (90) 30 (64) 435 (93) <0.001 
Numbers are presented as median (IQR) or numbers (%) 
† ECG denotes electrocardiogram; classification of the ECG was performed as suggested by 
Forest39  
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Clinical Significance 
 
• A simple algorithm incorporating hs-cTnT baseline values and absolute 
changes over two hours allowed a safe rule-out or accurate rule-in of Acute 
Myocardial Infarction.  
• Use of this algorithm may obviate the need for prolonged monitoring and serial 
blood sampling in 8 out of 10 unselected patients with acute chest pain and 
significantly shortens the time for triage in the emergency room.  
• 30-days survival was 100% in patients ruled-out for AMI 
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Online supplemental Appendix  
 
Supplemental Methods 
Adjudication of the final diagnosis  
Acute myocardial infarction was defined and cTnT levels interpreted as recommended in 
current guidelines.1-4 In brief, acute myocardial infarction was diagnosed when there was 
evidence of myocardial necrosis with a significant rise and/or fall in a clinical setting 
consistent with myocardial ischemia. Patients with acute myocardial infarction were further 
subdivided into acute myocardial infarction type 1 (primary coronary events) and acute 
myocardial infarction type 2 (ischemia due to increased demand or decreased supply, for 
example tachyarrhythmias or hypertensive crisis).1,2 
 For the derivation cohort, adjudication of final diagnoses was performed centrally in 
the core lab (University Hospital Basel) for all patients incorporating levels of hs-cTnT (see 
test characteristics above). More specifically, two independent cardiologists not directly 
involved in patient care reviewed all available medical records (including patient history, 
physical examination, results of laboratory testing including hs-cTnT levels, radiologic 
testing, ECG, echocardiography, cardiac exercise test, lesion severity and morphology in 
coronary angiography, discharge summary) pertaining to the patient from the time of ED 
presentation to 60-day follow-up. Late samples were available for adjudication of final 
diagnosis in all patients of the derivation cohort. In general, serial sampling was performed 
until at least 6h after presentation to the ED (90% of the patients). In 10% of patients with 
a low pretest probability for an acute myocardial infarction, serial sampling was stopped, at 
the discretion of the attending physician and in accordance with current ESC guidelines 
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once a second sample 3 hours after presentation to the ED was again negative.5 
In situations of diagnostic disagreement, cases were reviewed and adjudicated in 
conjunction with a third cardiologist. While discharge diagnoses often were correct and in 
agreement with the final adjudicated diagnosis, there were also cases where those 
diagnoses needed to be revised, most often because more information became available 
from medical testing during early follow-up, and more rarely, because the discharge 
diagnosis was not in agreement with the Universal Definition of acute myocardial 
infarction.  
 The 99th percentile (14 ng/l) was used as cut-off for myocardial necrosis. Absolute 
cTn changes were used to determine significant changes based on the diagnostic 
superiority of absolute over relative changes.6 Based on studies of the biological variation 
of cTn7,8 as well as on data from previous chest pain cohort studies,9,10 a significant 
absolute change was defined as a rise or fall of at least 10 ng/l within six hours, or, in an 
assumption of linearity, as an absolute change of 6ng/l within three hours, 4ng/l within two 
hours or 2ng/l within one hour. Alternative if discordant findings occurred, the longest time 
interval available was required to fulfill the change criteria. Predefined alternative 
diagnoses included “unstable angina” (UA), “Cardiac symptoms of origin other than 
coronary artery disease” and “non-cardiac chest pain”.  
 For the validation cohort, final diagnoses were adjudicated independently by one of 
two cardiologists. All adjudicated endpoints of acute coronary syndrome and 10% of non- 
acute coronary syndrome endpoints were adjudicated by both cardiologists to ensure 
agreement by consensus. Consensus was achieved for all endpoints. Late samples were 
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available for adjudication of final diagnosis in all patients of the validation cohort, which 
means that serial sampling was performed until at least 6h after presentation to the ED in 
all patients. Levels of the DxI Access Accu cTnI assay (Beckman Coulter, Chaska, 
Minnesota) were used for adjudication. This assay has a LoD of 0.01µg/l, a 99th percentile 
of 0.04µg/l and a 10% CV of 0.06µg/l. The 99th percentile (0.04µg/l) was used as cut-off 
for myocardial necrosis. A delta of ≥20%was used to detect a rising or falling pattern. The 
cTnI results from blood draws at presentation, and after 6 to 12 h (i.e. from routine care) 
were used for determination of necrosis.  
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Supplemental Results 
Further characterization of patients classified into the observation zone  
In the derivation cohort, 278 patients (24%) of patients did not fulfill neither the criteria for 
rule-out nor for rule-in and were classified in the so called “observational zone group”. 
Finally 41 of them (15%) were diagnosed with an acute myocardial infarction.  
In the validation cohort, 75 (14%) patients did not fulfill neither the criteria for rule-
out nor for rule-in and were classified in the so called “observational zone group”. Finally 
11 of them (15%) were diagnosed with an acute myocardial infarction.  
 
Diagnostic accuracy of the hs-cTnT algorithm in early vs. late presenters 
In the derivation cohort, 26% of the patients presented very early (≤2h) after the 
onset of symptoms. In this very early presenters group, 61% were assigned to the rule-out 
group, 22% in the observational group and 18% in the rule-in group. For the diagnosis of 
AMI, this resulted in a sensitivity and NPV for rule-out of 100% and 100% and a specificity 
and PPV for rule-in of 96% and 83%. 55% of patients presented early (<6h after the onset 
of symptoms). In this early presenters group, 59% were assigned to the rule-out group, 
24% in the observational group and 17% in the rule-in group. For the diagnosis of AMI, 
this resulted in a sensitivity and NPV for rule-out of 100% and 100% and a specificity and 
PPV for rule-in of 96% and 80%. In the late presenters group (>6h after presentation), 
61% were assigned to the rule-out group, 24% in the observational group and 16% in the 
rule-in group. For the diagnosis of AMI, this resulted in a sensitivity and NPV for rule-out of 
99% and 99.7% and a specificity and PPV for rule-in of 95% and 74%.  
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In the validation cohort, 47% of patients presented very early (≤2h) after the onset 
of symptoms. In this very early presenters group, 78% were assigned to the rule-out 
group, 14% in the observational group and 8% in the rule-in group. For the diagnosis of 
AMI, this resulted in a sensitivity and NPV for rule-out of 100% and 100% and a specificity 
and PPV for rule-in of 99.6% and 95%. 
82% of patients presented early (<6h after the onset of symptoms). In this early 
presenters group, 77% were assigned to the rule-out group, 15% in the observational 
group and 8% in the rule-in group. For the diagnosis of AMI, this resulted in a sensitivity 
and NPV for rule-out of 97% and 99.7% and a specificity and PPV for rule-in of 99% and 
85%. In the late presenters group (>6h after onset of symptoms) , 78% were assigned to 
the rule-out group, 14% in the observational group and 8% in the rule-in group. For the 
diagnosis of AMI, this resulted in a sensitivity and NPV for rule-out of 92% and 99% and a 
specificity and PPV for rule-in of 99% and 86%.  
 
Diagnostic accuracy of the hs-cTnT algorithm in patients with a normal hs-cTnT 
level at presentation 
With regards to hs-cTnT values at the time of inclusion, 67% of patients in the derivation 
cohort presented with hs-cTnT values below the 99th percentile. Of those, 89% were 
assigned to the rule-out group, 7% in the observational group and 4% in the rule-in group. 
For the diagnosis of AMI, this resulted in a sensitivity and NPV for rule-out of 97% and 
99% and a specificity and PPV for rule-in of 99% and 64%.  
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In the validation cohort, 80% of patients presented with hs-cTnT values below the 
99th percentile. Of those, 98% were assigned to the rule-out group, 2% in the 
observational group and 1% in the rule-in group. For the diagnosis of AMI, this resulted in 
a sensitivity and NPV for rule-out of 60% and 99.5% and a specificity and PPV for rule-in 
of 100% and 100%. 
 
Diagnostic accuracy of the hs-cTnT algorithm according to the TIMI risk score 
In the derivation cohort, 48% of patients had a TIMI risk score ≤1 and 52% had a 
TIMI risk score >1. In the group with a score ≤1, 87% were assigned to the rule-out group, 
9% in the observational group and 5% in the rule-in group. For the diagnosis of AMI, this 
resulted in a sensitivity and NPV for rule-out of 100% and 100% and a specificity and PPV 
for rule-in of 97% and 40%. In the group with a score >1, 35% were assigned to the rule-
out group, 38% in the observational group and 27% in the rule-in group. For the diagnosis 
of AMI, this resulted in a sensitivity and NPV for rule-out of 99% and 99.5% and a 
specificity and PPV for rule-in of 94% and 83%.  
In the validation cohort, 58% of patients had a TIMI risk score ≤1 and 42% had a 
TIMI risk score >1. In the group with a score ≤1, 96% were assigned to the rule-out group, 
2% in the observational group and 2% in the rule-in group. For the diagnosis of AMI, this 
resulted in a sensitivity and NPV for rule-out of 88% and 99.7% and a specificity and PPV 
for rule-in of 99.7% and 86%. In the group with a score >1, 52% were assigned to the rule-
out group, 32% in the observational group and 15% in the rule-in group. For the diagnosis 
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of AMI, this resulted in a sensitivity and NPV for rule-out of 97% and 99.1% and a 
specificity and PPV for rule-in of 97% and 85%.  
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Supplemental 
Table 1 
Baseline Characteristics of the Patients in the Derivation 
Cohort and Patients with Missing Samples 
 Study patients Patients with 
missing samples P Value 
 (n=1148) (n=964)  
Final diagnosis of AMI 187 (16) 193 (20) 0.03 
Age – yr  62 (51 – 74) 63 (49 – 76) 0.99 
Male gender – no. (%) 795 (69) 652 (68) 0.43 
Risk factors – no. (%)    
Hypertension 741 (65) 612 (64) 0.61 
Hypercholesterolemia 538(47) 423 (44) 0.17 
Diabetes 215 (19) 162 (17) 0.28 
Current smoking 292 (25) 245 (26) 0.96 
History of smoking 427 (37) 330 (34) 0.18 
History – no. (%)    
Coronary artery disease 412 (36) 336 (35) 0.62 
Previous myocardial infarction 280 (24) 234 (24) 0.95 
Previous revascularization 325 (28) 270 (28) 0.88 
Peripheral artery disease 78 (7) 58 (6) 0.47 
Previous stroke 57 (5) 56 (6) 0.39 
Creatinine clearance - (ml/min/m2) 91 (73 – 108) 88 (70 – 106) 0.13 
ECG findings – no. (%)†    
Left bundle branch block 38 (3) 26 (3) 0.41 
ST-segment elevation 20 (2) 20 (2) 0.58 
ST-segment depression 99 (9) 111 (12) 0.03 
T-wave inversion 88 (8) 97 (10) 0.05 
No significant ECG abnormalities 903 (79) 710 (74) 0.01 
† ECG denotes electrocardiogram; numbers are presented as median (IQR) or numbers (%) 
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Supplemental 
Table 2  
Baseline Characteristics of Patients in the Validation Cohort and 
Patients with Missing Samples  
 
Study patients Patients with 
missing samples 
Patients who 
presented  
>12 h after  
pain onset 
(n=279) 
P Value 
 
(n=517) (n=159)   
Final diagnosis of AMI 47 (9) 19 (12) 30 (11) 0.52 
Age – yr  54 (45 – 65) 52 (44-61) 54 (42-63) 0.11 
Male gender – no. (%) 316 (61) 91 (57) 166 (59) 0.67 
Risk factors – no. (%)     
Hypertension 268 (52) 80 (50) 129 (46) 0.32 
Hypercholesterolemia 269 (52) 76 (48) 138 (50) 0.61 
Diabetes 75 (15) 16 (10) 41 (15) 0.32 
Current smoking 127 (25) 41 (26) 79 (28) 0.51 
History of smoking 196 (38) 46 (29) 92 (33) 0.08 
History – no. (%)     
Coronary artery disease 135 (26) 40 (25) 60 (22) 0.35 
Previous myocardial infarction 103 (20) 33 (21) 44 (16) 0.29 
Previous revascularization 83 (16) 27 (17) 40 (14) 0.73 
Peripheral artery disease 11 (2) 6 (4) 7 (3) 0.51 
Previous stroke 59 (11) 13 (8) 22 (8) 0.21 
Creatinine clearance - (ml/min/m2) 77 (64-90) 73 (64-86) 76 (65-87) 0.45 
ECG findings – no. (%)†     
ECG indicative of AMI 5 (1) 5 (3) 5 (2) 0.15 
ECG indicative of ischemia not 
known to be old 20 (4) 6 (4) 18 (6) 0.60 
ECG indicative of ischemia known 
to be old 27 (5) 9 (6) 12 (4) 0.77 
No significant ECG abnormalities 465 (90) 137 (86) 244 (87) 0.33 
Numbers are presented as median (IQR) or numbers (%) † ECG denotes electrocardiogram; 
classification of the ECG was performed as suggested by Forest11 
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Suppl. Table 3 Characteristics of patients with AMI missed by the two hour hs-cTnT algorithm 
Patient Age  (yr) Gender 
History 
of CAD 
Previous 
AMI 
Time since 
onset or 
peak of 
symptoms 
ECG findings cTn max value Findings from 
coronary angiography 
# 1 71 male yes yes 12 h No evidence of ischemia 
22 ng/l 
(Roche hs-cTnT) 
Severe native vessel 
and vein graft disease. 
Left circumflex and vein 
graft stented. 
# 2  64 Male Yes No 8.5 h Non-specific ST-
segment changes 
100 ng/l  
(Beckman Coulter 
cTnI) 
Patient had 
echocardiogram 
showing no regional 
wall motion abnormality 
indicative of AMI. 
Endpoint listed as 
paroxysmal AF 
#3  64 Female Yes No 2.5 Normal 
300 ng/l 
(Beckman Coulter 
cTnI) 
Moderate coronary 
artery disease, no 
intervention performed. 
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